IRulya Therapeutics officer plans $133K share sale

The proposed transaction is listed through Merrill on NASDAQ.

Rhea-AI Filing Summary

IRulya Therapeutics Inc. officer Dirk Thye gave notice of a proposed sale of 3,700 common shares, with an aggregate market value of $133,328.85. The notice lists an approximate sale date of October 21, 2026, and names Merrill as broker and NASDAQ as the exchange.

Key Figures

Common shares to be sold: 3,700 shares Aggregate market value: $133,328.85 Approximate sale date: October 21, 2026

3 metrics

Common shares to be sold 3,700 shares Proposed sale by Dirk Thye

Aggregate market value $133,328.85 Proposed sale

Approximate sale date October 21, 2026 Proposed sale

Key Terms

Rule 144, RSU

2 terms

Rule 144 regulatory

"See the definition of “person” in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

RSU financial

"RSU"

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IRLA shares does officer Dirk Thye plan to sell?

Dirk Thye's notice covers a proposed sale of 3,700 IRLA common shares, with an aggregate market value of $133,328.85. It lists an approximate sale date of October 21, 2026.

Which broker and exchange are listed for Dirk Thye's proposed IRLA sale?

The notice lists Merrill as the broker and NASDAQ as the exchange for the proposed sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/21/2026 - 05:15 PM EDT Accepted by SEC EDGAR 10/21/2026 - 05:15 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001638945
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	IRULYA THERAPEUTICS INC
SEC File Number	001-38890
Address of Issuer	101 College Street, Suite 210 New Haven CONNECTICUT 06510
Phone	4159105717
Name of Person for Whose Account the Securities are To Be Sold	Dirk Thye
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON STOCK	MERRILL 555 CALIFORNIA ST SAN FRANCISCO CA 94104	3700	133328.85	1017063	10/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON STOCK	10/30/2025	RSU	IRULYA THERAPEUTICS INC			3700	10/30/2025	CASH

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	10/21/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Dirk Thye
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)